Cyllene reports preliminary EG110A results in spinal cord injury-related bladder dysfunction
Published in Brain/Neurology, Drugs development & discovery.
October 7, 2026
Cyllene Therapeutics presented interim results for EG110A at the International Continence Society meeting in Maastricht. The experimental gene therapy is being studied for urinary incontinence caused by neurogenic detrusor overactivity following spinal cord injury.
EG110A uses a non-replicating HSV-1 vector designed to inhibit CGRP-positive sensory neurons involved in bladder overactivity. Participants receive a treatment course through multiple injections into the bladder muscle.
The company reported an 87% reduction in incontinence episodes at 12 weeks among six responder patients across the first two dose cohorts. In three patients in the low-dose cohort, reductions were maintained through 52 weeks. The release reported no drug-related serious adverse events or dose-limiting toxicity; mild fever and nausea occurred shortly after injection.
These findings come from an ongoing, open-label dose-escalation study. The percentage describes a small responder subgroup, not all treated patients, and does not establish benefit against a randomized control group. Larger studies are needed to assess effectiveness and longer-term safety.
Source: Cyllene release via GlobeNewswire/StreetInsider, October 7, 2026.